Molecular Partners AG

NASDAQ:MOLN

Biotechnology

Healthcare
$2.67 +0.77%

+$0.03 today

Market cap
$100.28M
Beta
0.71
P/E (TTM)
-2.0
EPS (TTM)
-$1.55
52W Low $3.41High $5.36

Volume 0.00M

Average 0.00M

MOLN Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Molecular Partners AGNASDAQ: MOLN

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -CHF 323.66M, compared with -CHF 260.88M a year earlier.

Context

  • Retained earnings amounted to 370.3% of total assets at the end of Q1 FY2026, up 185.4 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -24.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CHF 323.66M-3.8% QoQ
Last fiscal yearDec 2025
-CHF 311.75M-26.6% YoY
Year agoMar 2025
-CHF 260.88M-24.1% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-24.1%——
1 year-26.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

CHF · from the balance sheet

Latest · FY2025
(311.75M) CHF
Year-over-year change
-26.6%

Retained Earnings vs competitors

How MOLN compares with its peers on the latest reported figures

  • Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -24.1% is the 7th highest of 9, against a peer median of -17.5%.
  • Retained earnings amounts to 370.3% of total assets for MOLN, versus a peer median of 334.7%.
MOLN Competitors
Retained Earnings for MOLN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RANIRani Therapeutics Holdings, Inc.Mar 2026-$139.61M USD-26.7%—269.1%
ELTXElicio Therapeutics, Inc.Mar 2026-$245.5M USD-19.6%—1082.0%
MOLNMolecular Partners AGMar 2026-CHF 323.66M CHF-24.1%—370.3%
PEPGPepGen Inc.Mar 2026-$378.88M USD-25.6%—242.4%
CRDFCardiff Oncology, Inc.Mar 2026-$442.38M USD-11.3%—899.6%
MISTMilestone Pharmaceuticals Inc.Mar 2026-$456.67M USD-17.6%—235.7%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026-$578.4M USD-17.1%—400.3%
NKTXNkarta, Inc.Mar 2026-$676.14M USD-17.3%—181.7%
ALECAlector, Inc.Mar 2026-$994.99M USD-14.4%—414.7%
Peer median (excluding MOLN) —-17.5%—334.7%

Competitors are the stored peer set for MOLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents71.81M87.95M67.31M63.87M82.65M
Short-term Investments61M161.2M119.58M85.57M10.41M
Net Receivables25.73M1.7M1.75M286K1.91M
Inventory20000
Other Current Assets0002.31M(1K)
Total Current Assets164.19M254.75M192.46M154.28M96.88M
Property, Plant & Equipment (Net)8.15M7.24M5.68M4.2M5.23M
Goodwill00000
Intangible Assets330K271K212K49K2K
Long-term Investments00000
Tax Assets00000
Other Non-current Assets1K(7.51M)000
Total Non-current Assets8.48M7.51M5.89M4.25M5.23M
Total Assets172.67M262.26M198.35M158.53M102.11M
Account Payables4.86M997K410K679K937K
Short-term Debt00000
Tax Payables855K0000
Deferred Revenue28.31M6.41M4.33M00
Other Current Liabilities00001K
Total Current Liabilities46.87M17.25M14.42M10.79M11.03M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)6.93M3.64M000
Other Non-current Liabilities6.74M2.55M5.06M4.88M8.31M
Total Non-current Liabilities18.51M9.84M7.51M6.11M10.75M
Total Liabilities65.38M27.09M21.92M16.89M21.77M
Common Stock3.23M3.6M3.64M4.04M4.04M
Retained Earnings(250.95M)(127.78M)(191.76M)(246.29M)(311.75M)
Accumulated OCI0(981K)000
Other Stockholders Equity0(0)(0)00
Minority Interest00000
Total Equity107.29M235.17M176.43M141.64M80.33M
Total Debt6.04M4.85M3.65M2.44M3.64M
Net Debt(65.77M)(83.1M)(63.66M)(61.43M)(79.01M)

Molecular Partners AG

NASDAQ:MOLN

Intrinsic Alpha fair value

Locked

Current Price

$2.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.